» Articles » PMID: 27070406

Knockout of NMDA-receptors from Parvalbumin Interneurons Sensitizes to Schizophrenia-related Deficits Induced by MK-801

Overview
Date 2016 Apr 13
PMID 27070406
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

It has been suggested that a functional deficit in NMDA-receptors (NMDARs) on parvalbumin (PV)-positive interneurons (PV-NMDARs) is central to the pathophysiology of schizophrenia. Supportive evidence come from examination of genetically modified mice where the obligatory NMDAR-subunit GluN1 (also known as NR1) has been deleted from PV interneurons by Cre-mediated knockout of the corresponding gene Grin1 (Grin1(ΔPV) mice). Notably, such PV-specific GluN1 ablation has been reported to blunt the induction of hyperlocomotion (a surrogate for psychosis) by pharmacological NMDAR blockade with the non-competitive antagonist MK-801. This suggests PV-NMDARs as the site of the psychosis-inducing action of MK-801. In contrast to this hypothesis, we show here that Grin1(ΔPV) mice are not protected against the effects of MK-801, but are in fact sensitized to many of them. Compared with control animals, Grin1(ΔPV)mice injected with MK-801 show increased stereotypy and pronounced catalepsy, which confound the locomotor readout. Furthermore, in Grin1(ΔPV)mice, MK-801 induced medial-prefrontal delta (4 Hz) oscillations, and impaired performance on tests of motor coordination, working memory and sucrose preference, even at lower doses than in wild-type controls. We also found that untreated Grin1(ΔPV)mice are largely normal across a wide range of cognitive functions, including attention, cognitive flexibility and various forms of short-term memory. Taken together these results argue against PV-specific NMDAR hypofunction as a key starting point of schizophrenia pathophysiology, but support a model where NMDAR hypofunction in multiple cell types contribute to the disease.

Citing Articles

Advances in the Treatment of Cognitive Impairment in Schizophrenia: Targeting NMDA Receptor Pathways.

Zhang T, Liu C, Zhong N, Wang Y, Huang Y, Zhang X Int J Mol Sci. 2024; 25(19).

PMID: 39408997 PMC: 11477438. DOI: 10.3390/ijms251910668.


The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia.

Uliana D, Lisboa J, Gomes F, Grace A Biochem Pharmacol. 2024; 228:116298.

PMID: 38782077 PMC: 11410545. DOI: 10.1016/j.bcp.2024.116298.


Generation of Rare Human NMDA Receptor Variants in Mice.

Sprengel R, Eltokhi A, Single F Methods Mol Biol. 2024; 2799:79-105.

PMID: 38727904 DOI: 10.1007/978-1-0716-3830-9_6.


D-serine reconstitutes synaptic and intrinsic inhibitory control of pyramidal neurons in a neurodevelopmental mouse model for schizophrenia.

Zhang X, Xu L, Zhu X, Tang Z, Dong Y, Yu Z Nat Commun. 2023; 14(1):8255.

PMID: 38086803 PMC: 10716516. DOI: 10.1038/s41467-023-43930-8.


Striatum-projecting prefrontal cortex neurons support working memory maintenance.

Wilhelm M, Sych Y, Fomins A, Alatorre Warren J, Lewis C, Capdevila L Nat Commun. 2023; 14(1):7016.

PMID: 37919287 PMC: 10622437. DOI: 10.1038/s41467-023-42777-3.


References
1.
Braga R, Reynolds G, Siris S . Anxiety comorbidity in schizophrenia. Psychiatry Res. 2013; 210(1):1-7. DOI: 10.1016/j.psychres.2013.07.030. View

2.
McHugh T, Jones M, Quinn J, Balthasar N, Coppari R, Elmquist J . Dentate gyrus NMDA receptors mediate rapid pattern separation in the hippocampal network. Science. 2007; 317(5834):94-9. DOI: 10.1126/science.1140263. View

3.
Mueser K, McGurk S . Schizophrenia. Lancet. 2004; 363(9426):2063-72. DOI: 10.1016/S0140-6736(04)16458-1. View

4.
Jackson M, Homayoun H, Moghaddam B . NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U S A. 2004; 101(22):8467-72. PMC: 420417. DOI: 10.1073/pnas.0308455101. View

5.
Coyle J . NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012; 38(5):920-6. PMC: 3446237. DOI: 10.1093/schbul/sbs076. View